Species-specific tropism determinants in the human immunodeficiency virus type 1 capsid
Retroviral tropism is determined in part by cellular restriction factors that block infection by targeting the incoming viral capsid. Indeed, human immunodeficiency virus type 1 (HIV-1) infection of many nonhuman primate cells is inhibited by one such factor, termed Lv1. In contrast, a restriction f...
Uložené v:
| Vydané v: | Journal of virology Ročník 78; číslo 11; s. 6005 |
|---|---|
| Hlavní autori: | , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
01.06.2004
|
| Predmet: | |
| ISSN: | 0022-538X |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Retroviral tropism is determined in part by cellular restriction factors that block infection by targeting the incoming viral capsid. Indeed, human immunodeficiency virus type 1 (HIV-1) infection of many nonhuman primate cells is inhibited by one such factor, termed Lv1. In contrast, a restriction factor in humans, termed Ref1, does not inhibit HIV-1 infection unless nonnatural mutations are introduced into the HIV-1 capsid protein (CA). Here, we examined the infectivity of a panel of mutant HIV-1 strains carrying substitutions in the N-terminal CA domain in cells that exhibit restriction attributable to Lv1 or Ref1. Manipulation of HIV-1 CA could alter HIV-1 tropism, and several mutations were identified that increased or decreased HIV-1 infectivity in a target-cell-specific manner. Many residues that affected HIV-1 tropism were located in the three variable loops that lie on the outer surface of the modeled HIV-1 conical capsid. Some tropism determinants, including the CypA binding site, coincided with residues whose mutation conferred on HIV-1 CA the ability to saturate Ref1 in human cells. Notably, a mutation that reverses the infectivity defect in human cells induced by CypA binding site mutation inhibits recognition by Ref1. Overall, these findings demonstrate that exposed variable loops in CA and a partial CypA "coat" can modulate restriction and HIV-1 tropism and suggest a model in which the exposed surface of the incoming retroviral capsid is the target for inhibition by host cell-specific restriction factors. |
|---|---|
| AbstractList | Retroviral tropism is determined in part by cellular restriction factors that block infection by targeting the incoming viral capsid. Indeed, human immunodeficiency virus type 1 (HIV-1) infection of many nonhuman primate cells is inhibited by one such factor, termed Lv1. In contrast, a restriction factor in humans, termed Ref1, does not inhibit HIV-1 infection unless nonnatural mutations are introduced into the HIV-1 capsid protein (CA). Here, we examined the infectivity of a panel of mutant HIV-1 strains carrying substitutions in the N-terminal CA domain in cells that exhibit restriction attributable to Lv1 or Ref1. Manipulation of HIV-1 CA could alter HIV-1 tropism, and several mutations were identified that increased or decreased HIV-1 infectivity in a target-cell-specific manner. Many residues that affected HIV-1 tropism were located in the three variable loops that lie on the outer surface of the modeled HIV-1 conical capsid. Some tropism determinants, including the CypA binding site, coincided with residues whose mutation conferred on HIV-1 CA the ability to saturate Ref1 in human cells. Notably, a mutation that reverses the infectivity defect in human cells induced by CypA binding site mutation inhibits recognition by Ref1. Overall, these findings demonstrate that exposed variable loops in CA and a partial CypA "coat" can modulate restriction and HIV-1 tropism and suggest a model in which the exposed surface of the incoming retroviral capsid is the target for inhibition by host cell-specific restriction factors.Retroviral tropism is determined in part by cellular restriction factors that block infection by targeting the incoming viral capsid. Indeed, human immunodeficiency virus type 1 (HIV-1) infection of many nonhuman primate cells is inhibited by one such factor, termed Lv1. In contrast, a restriction factor in humans, termed Ref1, does not inhibit HIV-1 infection unless nonnatural mutations are introduced into the HIV-1 capsid protein (CA). Here, we examined the infectivity of a panel of mutant HIV-1 strains carrying substitutions in the N-terminal CA domain in cells that exhibit restriction attributable to Lv1 or Ref1. Manipulation of HIV-1 CA could alter HIV-1 tropism, and several mutations were identified that increased or decreased HIV-1 infectivity in a target-cell-specific manner. Many residues that affected HIV-1 tropism were located in the three variable loops that lie on the outer surface of the modeled HIV-1 conical capsid. Some tropism determinants, including the CypA binding site, coincided with residues whose mutation conferred on HIV-1 CA the ability to saturate Ref1 in human cells. Notably, a mutation that reverses the infectivity defect in human cells induced by CypA binding site mutation inhibits recognition by Ref1. Overall, these findings demonstrate that exposed variable loops in CA and a partial CypA "coat" can modulate restriction and HIV-1 tropism and suggest a model in which the exposed surface of the incoming retroviral capsid is the target for inhibition by host cell-specific restriction factors. Retroviral tropism is determined in part by cellular restriction factors that block infection by targeting the incoming viral capsid. Indeed, human immunodeficiency virus type 1 (HIV-1) infection of many nonhuman primate cells is inhibited by one such factor, termed Lv1. In contrast, a restriction factor in humans, termed Ref1, does not inhibit HIV-1 infection unless nonnatural mutations are introduced into the HIV-1 capsid protein (CA). Here, we examined the infectivity of a panel of mutant HIV-1 strains carrying substitutions in the N-terminal CA domain in cells that exhibit restriction attributable to Lv1 or Ref1. Manipulation of HIV-1 CA could alter HIV-1 tropism, and several mutations were identified that increased or decreased HIV-1 infectivity in a target-cell-specific manner. Many residues that affected HIV-1 tropism were located in the three variable loops that lie on the outer surface of the modeled HIV-1 conical capsid. Some tropism determinants, including the CypA binding site, coincided with residues whose mutation conferred on HIV-1 CA the ability to saturate Ref1 in human cells. Notably, a mutation that reverses the infectivity defect in human cells induced by CypA binding site mutation inhibits recognition by Ref1. Overall, these findings demonstrate that exposed variable loops in CA and a partial CypA "coat" can modulate restriction and HIV-1 tropism and suggest a model in which the exposed surface of the incoming retroviral capsid is the target for inhibition by host cell-specific restriction factors. |
| Author | Sundquist, Wesley I Hatziioannou, Theodora Bieniasz, Paul D Von Schwedler, Uta K Cowan, Simone |
| Author_xml | – sequence: 1 givenname: Theodora surname: Hatziioannou fullname: Hatziioannou, Theodora organization: AIDS Research Center, 455 First Ave., New York, NY 10021, USA – sequence: 2 givenname: Simone surname: Cowan fullname: Cowan, Simone – sequence: 3 givenname: Uta K surname: Von Schwedler fullname: Von Schwedler, Uta K – sequence: 4 givenname: Wesley I surname: Sundquist fullname: Sundquist, Wesley I – sequence: 5 givenname: Paul D surname: Bieniasz fullname: Bieniasz, Paul D |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/15140998$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1kMtOwzAURL0ooqXwC8grdinX14kTL1HFo6gSC567yIlvVKPaCXGC1L8niLKa0czRLOaMzUIbiDEuYCUEFtePb5tVXkx-pQCyRIHAFQKkM7YAQEwyWXzM2VmMnwAiTVV6yuYiEyloXSzY-3NHtaOYxF9tXM2Hvu1c9NzSQL13wYQhchf4sCO-G70J3Hk_htbSRDsK9YF_u36MfDh0xAWvTRedPWcnjdlHujjqkr3e3b6sH5Lt0_1mfbNN6kzpIamsrqoMapND01gDUudTgpUyRV4JiQqsaqTCSoICbLSUKkWSFjE3U61xya7-dru-_RopDqV3sab93gRqx1jmQmMqCzWBl0dwrDzZsuudN_2h_L8CfwD2GGKy |
| CitedBy_id | crossref_primary_10_1128_JVI_79_22_14446_14450_2005 crossref_primary_10_1128_JVI_80_1_342_352_2006 crossref_primary_10_1186_s12977_015_0208_y crossref_primary_10_1128_AAC_01324_07 crossref_primary_10_1371_journal_ppat_1011830 crossref_primary_10_1146_annurev_genet_112414_054823 crossref_primary_10_3390_molecules27217162 crossref_primary_10_1016_j_virusres_2006_07_001 crossref_primary_10_1128_JVI_01563_17 crossref_primary_10_1128_JVI_79_10_6111_6121_2005 crossref_primary_10_1128_JVI_79_2_869_875_2005 crossref_primary_10_1128_JVI_00539_12 crossref_primary_10_1128_JVI_00648_11 crossref_primary_10_3389_fmicb_2022_854974 crossref_primary_10_1038_sj_mt_6300091 crossref_primary_10_7554_eLife_16269 crossref_primary_10_1128_JVI_00406_07 crossref_primary_10_1128_JVI_79_14_8870_8877_2005 crossref_primary_10_1128_JVI_80_5_2463_2471_2006 crossref_primary_10_1371_journal_ppat_1003577 crossref_primary_10_1128_JVI_01879_10 crossref_primary_10_1128_JVI_80_10_4683_4690_2006 crossref_primary_10_1016_j_mib_2006_06_011 crossref_primary_10_2217_17460794_1_1_71 crossref_primary_10_1371_journal_ppat_0040018 crossref_primary_10_1073_pnas_0505659102 crossref_primary_10_1128_JVI_00758_10 crossref_primary_10_1074_jbc_M110_187609 crossref_primary_10_1128_JVI_01519_06 crossref_primary_10_1016_j_virol_2008_06_037 crossref_primary_10_1074_jbc_M109_040618 crossref_primary_10_1016_j_micinf_2005_11_006 crossref_primary_10_1016_j_virol_2006_10_035 crossref_primary_10_1111_j_1348_0421_2008_00040_x crossref_primary_10_1038_gt_2010_40 crossref_primary_10_1128_JVI_79_18_11580_11587_2005 crossref_primary_10_3390_v5030981 crossref_primary_10_1038_mt_sj_6300091 crossref_primary_10_1128_JVI_05074_11 crossref_primary_10_1586_14760584_7_9_1419 crossref_primary_10_1038_nature12653 crossref_primary_10_1128_JVI_00283_06 crossref_primary_10_1186_s12977_021_00577_x crossref_primary_10_1371_journal_pbio_1000462 crossref_primary_10_1371_journal_ppat_1005050 crossref_primary_10_1128_JVI_00713_13 crossref_primary_10_1128_JVI_79_24_15586_15589_2005 crossref_primary_10_1073_pnas_0509996103 crossref_primary_10_1073_pnas_0600771103 crossref_primary_10_1371_journal_ppat_1008644 crossref_primary_10_1016_j_virol_2010_09_019 crossref_primary_10_1186_1742_4690_5_57 crossref_primary_10_2217_17460794_2_1_65 crossref_primary_10_1038_srep37489 crossref_primary_10_1099_vir_0_058180_0 crossref_primary_10_1074_jbc_M606066200 crossref_primary_10_1016_j_antiviral_2009_09_009 crossref_primary_10_1128_JVI_79_24_15175_15188_2005 crossref_primary_10_1128_JVI_00410_08 crossref_primary_10_1097_QAD_0b013e3282effa87 crossref_primary_10_1371_journal_ppat_1003352 crossref_primary_10_1016_j_virol_2006_03_015 crossref_primary_10_1128_JVI_79_10_6560_6564_2005 crossref_primary_10_1016_j_virol_2006_09_048 crossref_primary_10_1128_JVI_79_5_3139_3145_2005 crossref_primary_10_7554_eLife_35738 crossref_primary_10_1128_JVI_00270_06 crossref_primary_10_1016_j_virol_2015_10_014 crossref_primary_10_1128_JVI_79_15_9410_9418_2005 crossref_primary_10_1128_JVI_00516_06 crossref_primary_10_1186_1742_4690_6_100 crossref_primary_10_1128_JVI_79_1_176_183_2005 crossref_primary_10_1038_s41579_019_0225_2 crossref_primary_10_1128_JVI_00019_16 crossref_primary_10_1128_JVI_79_7_3930_3937_2005 crossref_primary_10_1089_hum_2005_16_1125 crossref_primary_10_1016_j_micinf_2014_08_017 crossref_primary_10_1074_jbc_M502145200 crossref_primary_10_1016_j_virol_2006_02_022 crossref_primary_10_1016_j_molcel_2004_12_001 crossref_primary_10_1186_1742_4690_6_21 crossref_primary_10_1128_JVI_00854_11 crossref_primary_10_1128_JVI_01551_06 crossref_primary_10_1016_j_virol_2013_03_021 crossref_primary_10_1128_JVI_79_24_15038_15042_2005 crossref_primary_10_1186_s12977_016_0300_y crossref_primary_10_1002_rmv_637 crossref_primary_10_1016_j_virol_2006_03_023 crossref_primary_10_1128_JVI_01549_13 crossref_primary_10_1371_journal_ppat_1003461 crossref_primary_10_1089_hum_2005_16_ft_113 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1128/JVI.78.11.6005-6012.2004 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Biology |
| ExternalDocumentID | 15140998 |
| Genre | Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S Journal Article |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: AI45405 – fundername: NIAID NIH HHS grantid: R01 AI050111 – fundername: NIAID NIH HHS grantid: R37 AI045405 – fundername: NIAID NIH HHS grantid: R01 AI045405 – fundername: NIAID NIH HHS grantid: AI50111 |
| GroupedDBID | --- -~X .55 .GJ 0R~ 18M 29L 2WC 39C 3O- 4.4 41~ 53G 5GY 5RE 5VS 6TJ 85S AAYJJ ABPPZ ACGFO ACNCT ADBBV AENEX AFFNX AGVNZ AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CGR CS3 CUY CVF D0S DIK E3Z EBS ECM EIF EJD F5P FRP GX1 H13 HYE HZ~ IH2 KQ8 MVM N9A NPM O9- OHT OK1 P2P PKN RHF RHI RNS RPM RSF TR2 UCJ UPT VH1 W2D W8F WH7 WOQ X7M Y6R YQT ZGI ZXP ~02 ~KM 7X8 AAFWJ AAGFI |
| ID | FETCH-LOGICAL-c569t-bd9bb50ca70ffda0397d9b2b6a87b13260d6f362b30602f933642e3d227a13292 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 111 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000221513400049&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0022-538X |
| IngestDate | Thu Sep 04 15:36:12 EDT 2025 Wed Feb 19 02:17:23 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c569t-bd9bb50ca70ffda0397d9b2b6a87b13260d6f362b30602f933642e3d227a13292 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | http://doi.org/10.1128/JVI.78.11.6005-6012.2004 |
| PMID | 15140998 |
| PQID | 71924386 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_71924386 pubmed_primary_15140998 |
| PublicationCentury | 2000 |
| PublicationDate | 2004-06-01 |
| PublicationDateYYYYMMDD | 2004-06-01 |
| PublicationDate_xml | – month: 06 year: 2004 text: 2004-06-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of virology |
| PublicationTitleAlternate | J Virol |
| PublicationYear | 2004 |
| SSID | ssj0014464 |
| Score | 2.1376944 |
| Snippet | Retroviral tropism is determined in part by cellular restriction factors that block infection by targeting the incoming viral capsid. Indeed, human... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 6005 |
| SubjectTerms | Amino Acid Sequence Animals Capsid - chemistry Cell Line DNA-(Apurinic or Apyrimidinic Site) Lyase - physiology HIV-1 - chemistry Humans Molecular Sequence Data Species Specificity Virion - chemistry |
| Title | Species-specific tropism determinants in the human immunodeficiency virus type 1 capsid |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/15140998 https://www.proquest.com/docview/71924386 |
| Volume | 78 |
| WOSCitedRecordID | wos000221513400049&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA6rq-DF92N95uA1a5ukTQuCiLio6LIHH70teRV6sK3b3QX_vZN2i17Eg5dSCoEyTCbfN5mZD6Fz6ksJSJkTRpUg3EhKYh0IktrQ15wZCJr1dP1HMRxGSRKPOuiy7YVxZZVtTKwDtSm0y5FfCMcUWBRelR_EaUa5u9WFgMYS6jIAMs6nRfJ9hwBEh7ezwmFbJ20dD40uHl7v-yKC937oJnECKalnUvLfYWZ93Aw2_vejm2h9ATPxdeMXW6hj82202ghPfu6gt1p23lbENVq6YiE8nRRlVr1j86M8Bmc5BnyIax0_nLlOksJYN3LC9WvieTaZVdjlcLGPtSzBr3fRy-D2-eaOLCQWiA7CeEqUiZUKPC2Fl6ZGeoBO4AtVoYyEAqIaeiZM4YxTwCw8msaMAV-xzFAqpJOop3toOS9ye4Bw4BmhAsNszC2nMow1QL3UauYHkVSa99BZa68xuLC7l5C5LWbVuLVYD-03Jh-XzaSNMcAR4J9xdPjn2iO01tTUuPzIMeqmsHntCVrR82lWTU5rz4DncPT0BdEcwfI |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Species-specific+tropism+determinants+in+the+human+immunodeficiency+virus+type+1+capsid&rft.jtitle=Journal+of+virology&rft.au=Hatziioannou%2C+Theodora&rft.au=Cowan%2C+Simone&rft.au=Von+Schwedler%2C+Uta+K&rft.au=Sundquist%2C+Wesley+I&rft.date=2004-06-01&rft.issn=0022-538X&rft.volume=78&rft.issue=11&rft.spage=6005&rft_id=info:doi/10.1128%2FJVI.78.11.6005-6012.2004&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-538X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-538X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-538X&client=summon |